The National Association for Proton Therapy shared a post on LinkedIn:
“New Research Published in The Lancet Group!
A landmark study led by Dr. Steven J. Frank, Professor of Radiation Oncology and Executive Director for Technology and Innovation at UT MD ANDERSON CANCER CENTER, has been officially published in The Lancet.
The publication reports a 10 percent higher 5-year overall survival rate in patients with oropharyngeal cancer receiving precise proton therapy vs. traditional radiation therapy, with significantly fewer side effects and improved quality of life. This first-of-its-kind study shows a rare combination of benefits with both reduced toxicity and improved survival for cancer patients.
Jennifer Maggiore, Executive Director of NAPT, noted that these findings provide long-sought, rigorous comparative evidence showing that reducing unnecessary radiation exposure with precise proton therapy can improve patient outcomes, survivorship, and quality of life.
NAPT applauds Dr. Frank and the multi-institutional research team for their contributions to rigorous science that moves the field forward and supports better patient outcomes.
Read the full study and NAPT’s press release.”